Coya Therapeutics, Inc.
COYA
$6.73
$0.233.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 423.50K | 3.69M | 3.55M | 9.55M | 9.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 423.50K | 3.69M | 3.55M | 9.55M | 9.55M |
| Cost of Revenue | 13.04M | 13.94M | 11.87M | 11.54M | 10.91M |
| Gross Profit | -12.62M | -10.26M | -8.31M | -1.98M | -1.35M |
| SG&A Expenses | 9.98M | 9.16M | 8.89M | 9.13M | 8.87M |
| Depreciation & Amortization | 27.20K | 27.20K | 27.20K | 27.20K | 27.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.05M | 23.13M | 20.78M | 20.69M | 19.80M |
| Operating Income | -22.62M | -19.44M | -17.22M | -11.14M | -10.25M |
| Income Before Tax | -21.06M | -17.86M | -15.60M | -9.98M | -9.38M |
| Income Tax Expenses | -720.30K | -720.30K | -720.30K | 723.90K | 723.90K |
| Earnings from Continuing Operations | -20.34 | -17.14 | -14.88 | -10.70 | -10.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.34M | -17.14M | -14.88M | -10.70M | -10.10M |
| EBIT | -22.62M | -19.44M | -17.22M | -11.14M | -10.25M |
| EBITDA | -22.59M | -19.42M | -17.20M | -11.11M | -10.22M |
| EPS Basic | -1.24 | -1.07 | -0.99 | -0.69 | -0.77 |
| Normalized Basic EPS | -0.80 | -0.70 | -0.64 | -0.38 | -0.43 |
| EPS Diluted | -1.24 | -1.07 | -0.99 | -0.69 | -0.77 |
| Normalized Diluted EPS | -0.80 | -0.70 | -0.64 | -0.38 | -0.43 |
| Average Basic Shares Outstanding | 65.02M | 63.21M | 60.95M | 55.63M | 50.36M |
| Average Diluted Shares Outstanding | 65.02M | 63.21M | 60.95M | 55.63M | 50.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |